AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25670823 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1 g) every 8 hours for 4-14 days
Number of subjects: 806
Study 25670823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam plus metronidazole
Number of subjects: 806
Study 25670823 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 806
Study 23974194 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 1111
Study 23974194 — intervention group
Group type: COMPARATOR
Intervention: Clodronate acid (CLO)
Number of subjects: 1111
Study 20642906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg
Number of subjects: 50
Study 20642906 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 50
Study 19025523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume (170 ml) ropivacaine (0.2%) with epinephrine
Number of subjects: 12
Study 19025523 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 15707562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone (150 microg/day) and Ethinylestradiol (15 microg/day)
Number of subjects: 150
Study 15707562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone (150 microg/day) and Ethinylestradiol (20 microg/day)
Number of subjects: 150
Study 15707562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone (200 microg/day) and Ethinylestradiol (15 microg/day)
Number of subjects: 150
Study 15707562 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses combined
Number of subjects: 150
Study 14616168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg (R10) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Number of subjects: 162
Study 14616168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (R20) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Number of subjects: 162
Study 14616168 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg (O) + amoxicillin 1,000 mg + clarithromycin 500 mg (AC)
Number of subjects: 162
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 25 mg once daily
Number of subjects: 24
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 50 mg once daily
Number of subjects: 24
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 100 mg once daily
Number of subjects: 24
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg once daily
Number of subjects: 24
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 24
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 24
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (up to 75 mg)
Number of subjects: 24
Study 10440416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Ticlopidine
Number of subjects: 24
Study 8706295 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg i.v.)
Number of subjects: 14
Study 1796819 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (Dermovate and another corticosteroid of differing potency) applied for 4 weeks
Number of subjects: 0
Study 1796819 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (another corticosteroid of differing potency) applied for 4 weeks
Number of subjects: 0
Study 6689490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg daily for 7 days)
Number of subjects: 12
Study 6689490 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Maalox, 105 ml daily for 7 days)
Number of subjects: 12
Study 6689490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg daily for 7 days) in healthy volunteers
Number of subjects: 12
Study 31342624 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 125 mg
Number of subjects: 88
Study 31342624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 31495601 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel of 44 plasma proteins along with age and apolipoprotein E (APOE) ε4
Number of subjects: 881
Study 31495601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 881
Study 29268794 — intervention group
Group type: EXPERIMENTAL
Intervention: List experiment method for measuring self-reported abortion
Number of subjects: 0
Study 29268794 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analyses
Number of subjects: 0
Study 29268794 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective measurement of lifetime experience of abortion
Number of subjects: 0
Study 26102262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1RM Split Squat (1RM-SS)
Number of subjects: 14
Study 26102262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1RM Bilateral Squat (1RM-BLS)
Number of subjects: 14
Study 23784898 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 g/day)
Number of subjects: 112
Study 23784898 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (10 g/day)
Number of subjects: 112
Study 23784898 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous recombinant GH (0 μg/kg/day)
Number of subjects: 112
Study 23784898 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant GH (3 μg/kg/day)
Number of subjects: 112
Study 23784898 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant GH (5 μg/kg/day)
Number of subjects: 112
Study 21451442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 150
Study 21451442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravitreal bevacizumab and triamcinolone (IVB/IVT)
Number of subjects: 150
Study 21451442 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 150
Study 20225472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine grit oval tip + oval posts
Number of subjects: 15
Study 20225472 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo Post File drill + circular posts
Number of subjects: 15
Study 20225472 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium grit oval tip + oval posts
Number of subjects: 15
Study 17288644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 102
Study 15042800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 10874656 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold concentrations of phenyl ethyl alcohol (PEA)
Number of subjects: 89
Study 10874656 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold concentrations of pyridine (PYR)
Number of subjects: 89
Study 10874656 — intervention group
Group type: COMPARATOR
Intervention: Odor detection thresholds for PEA and PYR
Number of subjects: 89
Study 9496213 — intervention group
Group type: EXPERIMENTAL
Intervention: Soda lime with 60 ml of water added (water group)
Number of subjects: 24
Study 9496213 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly exhausted soda lime (carbon dioxide group)
Number of subjects: 24
Study 9496213 — intervention group
Group type: COMPARATOR
Intervention: Fresh soda lime (control group)
Number of subjects: 24
Study 8201800 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (ZPC) 10 mg
Number of subjects: 7
Study 3815141 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-by-pass hemoconcentration
Number of subjects: 80
Study 3815141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemoconcentration)
Number of subjects: 80
Study 30924581 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention group
Number of subjects: 358
Study 30924581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocabulary intervention group
Number of subjects: 358
Study 30924581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined narrative and vocabulary intervention group
Number of subjects: 358
Study 30924581 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 358
Study 28711725 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred pressure ulcer prevention care bundle
Number of subjects: 1598
Study 28711725 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1598
Study 24903544 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL-PDT
Number of subjects: 32
Study 24903544 — intervention group
Group type: COMPARATOR
Intervention: PDT
Number of subjects: 32
Study 23907087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal stimulation and/or small volume enemas
Number of subjects: 0
Study 23907087 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 23907087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (rectal stimulation/enemas)
Number of subjects: 0
Study 23907087 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA presence
Number of subjects: 0
Study 23907087 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 0
Study 21533739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture at tender points located in area M, positive to Needle Contact Test (NCT)
Number of subjects: 94
Study 21533739 — intervention group
Group type: COMPARATOR
Intervention: Ear acupuncture at unsuitable area S
Number of subjects: 94
Study 19118966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 50mg/kg per day
Number of subjects: 122
Study 19118966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 19118966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine in medication stratum
Number of subjects: 122
Study 19118966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine in nutrition stratum
Number of subjects: 122
Study 17562631 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention during chemotherapy
Number of subjects: 123
Study 17562631 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control) during matched chemotherapy treatment
Number of subjects: 123
Study 15319676 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E (300 microg of each antigen B and E)
Number of subjects: 0
Study 15319676 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Number of subjects: 0
Study 15319676 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120 B/E
Number of subjects: 0
Study 11439380 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 67
Study 11439380 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP index
Number of subjects: 67
Study 9934894 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimistic survival forecasts
Number of subjects: 120
Study 9934894 — intervention group
Group type: COMPARATOR
Intervention: Pessimistic survival forecasts
Number of subjects: 120
Study 9934894 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived benefit
Number of subjects: 120
Study 9934894 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice style
Number of subjects: 120
Study 7753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental test with graphemic processing
Number of subjects: 0
Study 7753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposition test with graphemic processing
Number of subjects: 0
Study 7753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental test with semantic processing
Number of subjects: 0
Study 7753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposition test with recognition failure conditionalization
Number of subjects: 0
Study 7753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental and opposition tests
Number of subjects: 0
Study 7753947 — intervention group
Group type: COMPARATOR
Intervention: Intentional test
Number of subjects: 0
Study 2147241 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 64
Study 2147241 — intervention group
Group type: EXPERIMENTAL
Intervention: Local/regional anaesthesia
Number of subjects: 64
Study 6986409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 0
Study 6986409 — intervention group
Group type: COMPARATOR
Intervention: Bilateral surgical adrenalectomy
Number of subjects: 0
Study 31991566 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 70
Study 31991566 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 31991566 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition in PDAC patients
Number of subjects: 70
Study 31991566 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition in non-PDAC patients
Number of subjects: 70
Study 30916579 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-Assisted Soft-Tissue Mobilization (IASTM) using the Graston technique
Number of subjects: 11
Study 30916579 — intervention group
Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 11
Study 28503750 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg daily for 26 weeks
Number of subjects: 24
Study 28503750 — intervention group
Group type: COMPARATOR
Intervention: Structured lifestyle modification (dieting restriction by 400 kilocalories/d plus moderate-intensity aerobic exercise 200 min/wk) for 26 weeks
Number of subjects: 24
Study 26628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Case Management integrated with Problem-Solving Therapy (CM-PST)
Number of subjects: 171
Study 26628206 — intervention group
Group type: COMPARATOR
Intervention: Clinical Case Management (CM)
Number of subjects: 171
Study 26628206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CM and CM-PST)
Number of subjects: 171
Study 23313304 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS pentagonal model (PM)
Number of subjects: 108
Study 23313304 — intervention group
Group type: EXPERIMENTAL
Intervention: Van Der Gaag 5-factor model (VDG)
Number of subjects: 108
Study 23313304 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analyses between PM and VDG models
Number of subjects: 108
Study 21523719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 19848049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 24
Study 19848049 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 24
Study 16763658 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos Fit IOL (two-point haptic)
Number of subjects: 93
Study 16763658 — intervention group
Group type: COMPARATOR
Intervention: Akreos Adapt IOL (four-point haptic)
Number of subjects: 93
Study 12690054 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa treatment
Number of subjects: 8
Study 12690054 — intervention group
Group type: EXPERIMENTAL
Intervention: STN stimulation
Number of subjects: 8
Study 12690054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (L-dopa + STN stimulation)
Number of subjects: 8
Study 12690054 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 8
Study 12690054 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa, STN stimulation, and combined treatment
Number of subjects: 8
Study 11050641 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical postprocessing technique for MR images
Number of subjects: 10
Study 11050641 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized dual fast spin-echo MR images
Number of subjects: 10
Study 8863019 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 40
Study 8863019 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 40
Study 8863019 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 40
Study 1736456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (15 +/- 3.5 mg of nicotine in 16 hours)
Number of subjects: 289
Study 1736456 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 289
Study 6845123 — intervention group
Group type: EXPERIMENTAL
Intervention: Long leg TED hose
Number of subjects: 77
Study 6845123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential compression devices (SCD)
Number of subjects: 77
Study 6845123 — intervention group
Group type: COMPARATOR
Intervention: Control group (96 patients)
Number of subjects: 77
Study 3782631 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 8341
Study 3782631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8341
Study 31046528 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquaintance sexual violence scenario
Number of subjects: 296
Study 31046528 — intervention group
Group type: EXPERIMENTAL
Intervention: Victims of sexual violence
Number of subjects: 296
Study 31046528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvictims with stronger just-world beliefs
Number of subjects: 296
Study 31046528 — intervention group
Group type: COMPARATOR
Intervention: Stranger sexual violence scenario
Number of subjects: 296
Study 29431272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Number of subjects: 62
Study 29431272 — intervention group
Group type: COMPARATOR
Intervention: Sitting interrupted by regular brief activity breaks
Number of subjects: 62
Study 27581575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counseling + mass media + community mobilization (IPC + MM + CM)
Number of subjects: 2200
Study 27581575 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition counseling + less intensive mass media + community mobilization (nonintensive)
Number of subjects: 2200
Study 27581575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group
Number of subjects: 2200
Study 27581575 — intervention group
Group type: COMPARATOR
Intervention: Nonintensive group
Number of subjects: 2200
Study 24529603 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-convergent therapy (MCT) for 16 weeks
Number of subjects: 66
Study 24529603 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 66
Study 24529603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 22378825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal ethanol exposure (administered to dams through a liquid diet)
Number of subjects: 0
Study 22378825 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (to target TrpV1)
Number of subjects: 0
Study 22378825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard oil (to target TrpA1)
Number of subjects: 0
Study 22378825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 22378825 — intervention group
Group type: COMPARATOR
Intervention: Control group (ad libitum access to an iso-caloric iso-nutritive liquid diet)
Number of subjects: 0
Study 20470336 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg x kg(‐1) in 5 ml of honey)
Number of subjects: 92
Study 20470336 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-Ketamine (0.25 mg x kg(‐1) midazolam mixed with 1 mg x kg(‐1) ketamine in 5-ml honey)
Number of subjects: 92
Study 20470336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5-ml honey alone)
Number of subjects: 92
Study 18257184 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with TDP radiation
Number of subjects: 158
Study 18257184 — intervention group
Group type: COMPARATOR
Intervention: L-Dopa (Control)
Number of subjects: 158
Study 16416346 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 treatment for hypothyroidism
Number of subjects: 85
Study 16416346 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals with the same TSH levels
Number of subjects: 85
Study 12801161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline at a dosage of 200 mg/day during the 8-week open-label extension phase.
Number of subjects: 0
Study 12801161 — intervention group
Group type: COMPARATOR
Intervention: Sertraline at a dosage of 100 mg/day during the acute phase.
Number of subjects: 0
Study 12801161 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders from the acute phase.
Number of subjects: 0
Study 12801161 — intervention group
Group type: COMPARATOR
Intervention: Both phases (acute and extension).
Number of subjects: 0
Study 10929571 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion-SR 150 mg/day
Number of subjects: 30
Study 10929571 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion-SR 300 mg/day
Number of subjects: 30
Study 10929571 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion-SR
Number of subjects: 30
Study 8842507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (2 mg/kg iv over 10 minutes followed by 0.007 mg/kg/min)
Number of subjects: 182
Study 8842507 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (0.9% saline solution)
Number of subjects: 182
Study 1352662 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 2 mg.kg‐1
Number of subjects: 82
Study 1352662 — intervention group
Group type: EXPERIMENTAL
Intervention: nitroglycerin 3 micrograms.kg‐1
Number of subjects: 82
Study 1352662 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 82
Study 6378231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1200 mg
Number of subjects: 15
Study 6378231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30979733 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting Machine (GBM)
Number of subjects: 334
Study 30979733 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 334
Study 30979733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal RF classifier
Number of subjects: 334
Study 30979733 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised clustering analysis
Number of subjects: 334
Study 30632328 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous ventriculoperitoneal (VP) shunting
Number of subjects: 98
Study 30632328 — intervention group
Group type: COMPARATOR
Intervention: Delayed ventriculoperitoneal (VP) shunting
Number of subjects: 98
Study 27343417 — intervention group
Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 407